2023年12月最新中科院分区表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CANCER IMMUNOLOGY IMMUNOTHERAPY CANCER IMMUNOL IMMUN （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.7
51人评分
我要评分
声誉 8.8 影响力 6.5 速度 8.9 | |||||||||||||||||||||||||||||
| 期刊ISSN | 0340-7004 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||
| E-ISSN | 1432-0851 | |||||||||||||||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 5.8 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||
| 实时影响因子 | 截止2024年3月26日：4.902 | |||||||||||||||||||||||||||||
| 2022-2023自引率 | 1.70%点击查看自引率趋势图 | |||||||||||||||||||||||||||||
| 五年影响因子 | 6.1 | |||||||||||||||||||||||||||||
| h-index | 104 | |||||||||||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||
| 期刊官方网站 | https://www.springer.com/262 | |||||||||||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/ciim | |||||||||||||||||||||||||||||
| 作者指南网址 | https://www.springer.com/262/submission-guidelines | |||||||||||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CANCER IMMUNOLOGY IMMUNOTHERAPY的语言要求，还能让CANCER IMMUNOLOGY IMMUNOTHERAPY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CANCER IMMUNOLOGY IMMUNOTHERAPY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||||||
| 通讯方式 | SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013 | |||||||||||||||||||||||||||||
| 出版商 | Springer Berlin Heidelberg | |||||||||||||||||||||||||||||
| 涉及的研究方向 | 医学-免疫学 | |||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||||||
| 出版年份 | 1976 | |||||||||||||||||||||||||||||
| 年文章数 | 219点击查看年文章数趋势图 | |||||||||||||||||||||||||||||
| Gold OA文章占比 | 32.52% | |||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 91.78% | |||||||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0340-7004%5BISSN%5D | |||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均1月 | |||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CANCER IMMUNOLOGY IMMUNOTHERAPY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors Author: Wei, Chen; Wang, Mengyu; Gao, Quanli; Yuan, Shasha; Deng, Wenying; Bie, Liangyu; Ma, Yijie; Zhang, Chi; Li, Shuyi; Luo, Suxia; Li, Ning Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 23-37. DOI: 10.1007/s00262-022-03221-5 PubMed DOI |
| 2. | Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer Author: Ding Jianyi; Gan Haili; Bo, Yin; Yang Meiqin; Huang Baoyou; Hu Haoran; Li Fang; Zheng Qingliang; Han Lingfei Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 73-85. DOI: 10.1007/s00262-022-03226-0 PubMed DOI |
| 3. | Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint Author: Lei, Jie; Zhu, Jianfei; Hui, Bengang; Jia, Chenghui; Yan, Xiaolong; Jiang, Tao; Wang, Xiaoping Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 101-124. DOI: 10.1007/s00262-022-03235-z PubMed DOI |
| 4. | Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer Author: Ji, Niannian; Long, Meijun; Garcia-Vilanova, Andreu; Ault, Russell; Moliva, Juan, I; Yusoof, Kizil A.; Mukherjee, Neelam; Curiel, Tyler J.; Dixon, Hong; Torrelles, Jordi B.; Svatek, Robert S. Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 125-136. DOI: 10.1007/s00262-022-03236-y PubMed DOI |
| 5. | The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer Author: Nose, Yohei; Saito, Takuro; Yamamoto, Kei; Yamashita, Kotaro; Tanaka, Koji; Yamamoto, Kazuyoshi; Makino, Tomoki; Takahashi, Tsuyoshi; Kawashima, Atsunari; Haruna, Miya; Hirata, Michinari; Ueyama, Azumi; Iwahori, Kota; Satoh, Taroh; Kurokawa, Yukinori; Eguchi, Hidetoshi; Doki, Yuichiro; Wada, Hisashi Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 169-181. DOI: 10.1007/s00262-022-03240-2 PubMed DOI |
| 6. | TIGIT blockade enhances tumor response to radiotherapy via a CD103+dendritic cell-dependent mechanism Author: Zhao, Kaikai; Jiang, Liyang; Si, Youjiao; Zhou, Shujie; Huang, Zhaoqin; Meng, Xiangjiao Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 193-209. DOI: 10.1007/s00262-022-03227-z PubMed DOI |
| 7. | Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis Author: Lv, Liwei; Wu, Yuchen; Shi, Han; Sun, Xuefei; Deng, Zixin; Huo, Hongjia; Li, Ruonan; Liu, Yuanbo Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 211-221. DOI: 10.1007/s00262-022-03246-w PubMed DOI |
| 8. | Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis Author: Jiang, Guangyi; Ng, Yu Yang; Tay, Johan C. K.; Du, Zhicheng; Xiao, Lin; Wang, Shu; Zhu, Jianqing Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 223-234. DOI: 10.1007/s00262-022-03247-9 PubMed DOI |
| 9. | Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays Author: Lou, Ning; Zheng, Cuiling; Wang, Yanrong; Liang, Caixia; Tan, Qiaoyun; Luo, Rongrong; Zhang, Lei; Xie, Tongji; Shi, Yuankai; Han, Xiaohong Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 1, pp. 235-247. DOI: 10.1007/s00262-022-03242-0 PubMed DOI |
| 10. | Interleukin-32 gamma promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma Author: Yan, Haimeng; He, Donghua; Qu, Jianwei; Liu, Yang; Xu, Ruyi; Gu, Huiyao; Chen, Jing; Li, Yi; Zhang, Enfan; Zhao, Yi; He, Jingsong; Cai, Zhen Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; Vol. 72, Issue 2, pp. 327-338. DOI: 10.1007/s00262-022-03241-1 PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共144条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
